This Week in Medical Journals: August 2026 Highlights

This monthly roundup pulls together the developments worth a UK clinician's attention. For weekly digests tailored to your specialty — every article from the top five journals, summarised — start your free trial.

August 2026 is a Scottish month. The SMC published seven acceptances in a single batch on 10 August, three of which land squarely in primary care. Alongside them, a migraine appraisal that changes what a familiar drug is for. Here is what changed and where to read the detail.

Migraine: atogepant is now for the attack, not just for prevention

The change most likely to catch people out is a drug they already know.

NICE recommended atogepant (Aquipta) as an option for the acute treatment of migraine in adults — technology appraisal TA1172, published 30 June 2026. Atogepant was already recommended for preventing migraine under TA973. It now has both indications, under two separate appraisals, and they are not interchangeable.

Eligibility for the acute indication is defined by what has already failed:

• at least two triptans tried, and they did not work well enough — or triptans are contraindicated or not tolerated; and
• NSAIDs and paracetamol tried, and they did not work well enough.

Where atogepant and rimegepant are both suitable, NICE asks prescribers to use the least expensive option, taking account of dosage, price per dose, administration costs and any commercial arrangements. The two have not been compared head-to-head in a trial; an indirect comparison suggests similar pain reduction at two hours.

The practical point for primary care: if you have a patient on atogepant, it is now worth knowing which appraisal they are being treated under. Prevention and acute treatment are different prescriptions with different criteria.

Scotland: seven SMC acceptances, three of them for primary care

The SMC published advice on seven medicines on 10 August 2026. All seven were accepted. Three matter outside specialist clinics.

Sodium zirconium cyclosilicate (Lokelma) — accepted for adults with hyperkalaemia who have chronic kidney disease or heart failure. This is the one with the widest reach. Hyperkalaemia is the routine obstacle to optimising renin-angiotensin blockade in exactly the patients who benefit most from it, and a potassium binder changes that conversation.

Relevant reading: SGLT2 inhibitors in CKD and NICE NG106 heart failure.

Upadacitinib (Rinvoq) — accepted for giant cell arteritis. GCA is usually suspected in primary care and confirmed elsewhere, so this changes what happens after referral rather than the referral itself. The urgency of the suspicion is unchanged.

House dust mite allergen extract (Acarizax) — accepted for patients aged 18 to 65 with moderate to severe house dust mite allergic rhinitis.

The remaining four are specialist: zilucoplan (Zilbrysq) for generalised myasthenia gravis, levodopa/carbidopa/entacapone (Lecigon) for advanced Parkinson's disease, cabozantinib for certain advanced neuroendocrine tumours, and dostarlimab (Jemperli) with chemotherapy for a specific advanced endometrial cancer.

As always, SMC advice applies to NHS Scotland. It does not change the position in England and Wales, where NICE guidance governs.

Neurology: NG220 diagnosis updated to the 2024 McDonald criteria

NICE last updated NG220, the multiple sclerosis guideline, on 3 June 2026. The substantive change is to the diagnosis recommendations, which now take account of the revised 2024 McDonald criteria.

This is a diagnostic-criteria update rather than a change to management, so its effect is felt at the point of referral and confirmation rather than in ongoing care.

Menopause: the fezolinetant position in Scotland

A recap for completeness, since it closes a thread from July. The SMC accepted fezolinetant for restricted use in NHS Scotland — SMC2898, published 13 July 2026 — for moderate to severe vasomotor symptoms in patients for whom HRT is not suitable. It was a resubmission; the SMC did not accept fezolinetant first time round in 2025. Nothing changes for England and Wales, where TA1143 already applies.

Full summary: What to offer when HRT isn't suitable.

The pattern this month

Last quarter's through-line was prescribing change in primary care. This month's is narrower and more technical: two of the four items are about which version of a treatment a patient is on — atogepant under prevention or acute criteria, MS diagnosed under old or revised criteria. The Lokelma acceptance is the one that changes a decision rather than a definition, and only in Scotland for now.

If you see adults in general practice, the highest-yield item is the potassium binder, because it unblocks something you were already trying to do.

Every week, thousands of papers and a steady stream of guidance updates land. Staying current is foundational to good practice — and hard to do in a full clinical week. That is why The Monday Clinical Brief exists: to distil the signal from the noise and deliver it to your inbox every Monday, tailored to your specialty. For the bigger picture, see our pillar guide on how to keep up with the medical literature.

Start your free trial — £20 a year, no advertising.